

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110344 A3

(51) International Patent Classification⁷: C07D 417/12,
417/14, 401/04, 403/04, 403/14, 413/04, 413/14, A61K
31/541, 31/54, A61P 11/00, 25/28, 25/00, 9/00

(21) International Application Number:
PCT/SE2004/000901

(22) International Filing Date: 9 June 2004 (09.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0301744-9 13 June 2003 (13.06.2003) SE
0303493-1 19 December 2003 (19.12.2003) SE

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JOHANSSON, An-
ders [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Möl-
ndal (SE). PERSSON, Joachim [SE/SE]; AstraZeneca R
& D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: ASTRAZENECA; Global Intellectual Property,
S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)


Published:

— with international search report

(88) Date of publication of the international search report:
17 February 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NEW AZETIDINE COMPOUNDS



5,6,7,8-tetrahydroquinolinyl; 5,6,7,8-tetrahydroisoquinolinyl;
1-benzo[b]thiophen-4-yl; 1-benzo[b]thiophen-3-yl; isoquinolinyl;
1-benzo[b]thiophen-7-yl; 1-benzo[b]thiophen-2-yl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or
an enantiomer thereof or any salt thereof; to a pharmaceutical composition containing said compounds and to the use of said
compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I and to
new intermediates used in the preparation thereof.

(57) Abstract: The present invention relates to a compound of
the general formula (I) wherein Het is an optionally substituted
4-, 5-, 6- or 7-membered heterocyclic ring having at least one
nitrogen atom; R1 is hydrogen, hydroxy, C₁-C₄ alkyl, C₃-C₄
cycloalkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl; R2 and R3 is each
and independently selected from hydrogen, C₁-C₄ alkyl, C₃-C₄
cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, halogen
and cyano, provided that R2 and R3 may not both be hydrogen;
R4 is C₁-C₄ alkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl or C₂-C₄
alkynyl; Ar is an optionally substituted aromatic ring system se-
lected from pyridinyl; 1-naphthyl; 5,6,7,8-tetrahydro-1-naphthyl;
quinolinyl; 2,3-dihydro-1,4-benzodioxinyl; 1,3-benzodioxolyl;

WO 2004/110344 A3